Join experts from Cardinal Health Regulatory Sciences (CHRS) and the venture capital community in this discussion on regulatory due diligence. They will share the process of developing a “de-risking” framework, and provide insights throughout the regulatory lifecycle from discovery to early development and from clinical to post approval. Explore the processes that aid in decision-making related to product and portfolio development.
- De-risking model for drug discovery & development
- Assessing your technology readiness level (TRL)
- Keys to conducting regulatory due diligence
- Regulatory considerations for cell and gene therapy development
Registration – https://launchbio.org/feature/derisking-drug-development
From Sep 17, 2020 10:00AM to Sep 17, 2020 11:00AM at